After receiving the approval by the US Bankruptcy Court for the District of Delaware, Akorn, Inc. has successfully completed sale to the company’s term loan lenders, thus exiting the Chapter 11 protection it had filed for early this year. “Today marks the start of an exciting new chapter for Akorn,” said CEO Doug Boothe.
Akorn Completes Sale Following Bankruptcy Filing
US Firm Exits Chapter 11 Protection
Akorn aims for “long-term growth and a brighter future” after exiting Chapter 11 protection that it had filed for in May 2020. After completing the sale to its lenders, the company is now operating as a private entity under the legal name, Akorn Operating Company LLC.
More from Deals
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.
• By
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
• By
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
More from Business
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.